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Abstract
Background: The incidence of cardiovascular disease is considerably disparate among different racial and ethnic
populations. While dobutamine stress echocardiography (DSE) has been shown to be useful in Caucasian patients,
its role among ethnic minority groups remains unclear. This study aimed to investigate the prognostic importance
of DSE in three ethnic groups in the UK.
Methods: DSE was performed on 6231 consecutive patients. After exclusions, 5329 patients formed the study (2676
[50.2 %] Indian Asian, 2219 [41.6 %] European white and 434 [8.1 %] Afro-Caribbean). Study outcome measures
were non-fatal cardiac events (NFCE) and all-cause mortality.
Results: There were 849 (15.9 %) NFCE and 1365 (25.6 %) deaths over a median follow-up period of 4.6 years. In
total 1174 (22 %) patients had inducible myocardial ischaemia during DSE, 859 (16.1 %) had fixed wall motion
abnormalities and 3645 (68.4 %) patients had a normal study. Ethnicity did not predict events. Among the three
ethnic groups, ischaemia on DSE was associated with 2 to 2.5 times the risk of non-fatal cardiac events and 1.2 to
1.4 times the risk of all-cause mortality. Peak wall motion score index was the strongest independent predictor of
non-fatal cardiac events and all-cause mortality in all groups. The C statistic for the prediction of NFCE and all-cause
mortality were significantly higher when DSE parameters were added to the standard risk factors for all ethnic
groups.
Conclusions: DSE is a strong predictor of NFCE and all-cause mortality and provides predictive information beyond
that provided by standard risk factors in three major racial and ethnic groups. No major differences among racial
and ethnic groups in the predictive value of DSE was detected.
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Background
The UK has become more ethnically diverse with an in-
crease in both the number and proportion of Afro-
Caribbean and Asian minority ethnic groups. In 2011, all
Afro-Caribbean and Asian minority groups accounted for
13% of the population in England and Wales [1]. The inci-
dence of cardiovascular disease (CVD) is considerably
disparate among different racial and ethnic popula-
tions [2]. CVD mortality is 40 % higher in Indian
Asians compared with European white groups [3] and
is significantly greater among Afro-Caribbeans com-
pared with European whites [2, 4]. Coronary artery dis-
ease (CAD) is the leading cause of premature CVD
death in European whites and Asians; however, in Afro-
Caribbean populations death from stroke is the leading
cause [5]. Although conventional risk factors contribute
to the differences in CVD, they do not adequately ex-
plain the excess risk noted in Afro-Caribbean and
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Indian Asian populations [2]. However, there may be
certain ethnic specific CVD risk factors [3, 6].
Afro-Caribbean and Indian Asian populations are
under represented in epidemiological and cardiovascular
research trials [7]. As a result, minority ethnic groups
may be at risk of significant disadvantage across a range
of health indicators. Reporting racial information is im-
portant since findings from European white populations
may not necessarily be extrapolated to other ethnic groups,
given the observed differences in CVD mortality.
Prior research has demonstrated a survival difference
between white, black, and Hispanic ethnic groups under-
going exercise treadmill testing, even after adjustment
for patient demographics, baseline electrocardiography
abnormalities, CVD co-morbidities and risk factors, and
exercise test findings [8]. Dobutamine stress echocardi-
ography (DSE) is a widely accepted and useful non-
invasive test for the diagnosis, risk stratification and
prognosis of CAD [9–12], as well as having greater spe-
cificity and sensitivity for CAD diagnosis compared to
exercise treadmill testing. In addition, DSE has provided
important prognostic information among different age
groups [13], in men and women [14], as well as in
patients with diabetes [15] and renal disease [16]. How-
ever, despite the available evidence, no study has investi-
gated the role of DSE in predicting outcome amongst
Afro-Caribbean, Caucasian and Indian Asian patients or
determined whether myocardial ischaemia and ischae-
mic burden have the same prognostic power in these
different ethnic populations. Therefore the aim of this
prospective cohort study was to evaluate the role of DSE
in the prediction of non-fatal cardiac events (NFCE) and
all cause mortality by ethnic group. We studied a large
cohort of consecutive patients referred for DSE and eval-
uated outcomes in UK Afro-Caribbean, European whites
and Indian Asian patients.
Methods
Study design and patients
The study population consisted of 6231 consecutive pa-
tients undergoing DSE for the evaluation of angina pec-
toris or shortness of breath on exertion between June
2006 to September 2011 in the outpatient setting. All pa-
tients were required to provide informed consent before
testing and the local research ethics committee approved
the study. Ethnicity was obtained through self-report
using the 2001 UK Census categorisation for classifying
ethnicity. Exclusion criteria included mixed ethnic groups,
Chinese ethnicity, patients referred for viability assess-
ment only, asymptomatic patients awaiting non-cardiac
surgery, patients with severe valve disease, and patients
who did not provide signed informed consent.
Before DSE, a structured history and medical record
review was performed to document symptoms, medical
history, medication use, cardiac risk factors, and previ-
ous cardiac events and procedures. The estimation of
the pre-test probability of CAD was determined using
previously described criteria, which included the pres-
ence and characteristics of chest pain, age, gender, and
presence of greater than or equal to three CAD risk fac-
tors [17]. Patients were categorised into low, intermediate
or high pre-test probability. For patients who underwent
multiple DSE tests during this period, only the first DSE
was considered in the analysis.
Follow-up data was obtained by investigators blinded
to the DSE result and information was collated by con-
tacting patients or a family member, general practi-
tioners, and reviewing hospital records to inquire about
interim hospital admissions, outpatient diagnosis of car-
diovascular events, and deaths. The date of the last re-
view or consultation was used to calculate the duration
of follow-up through to June 2013.
Dobutamine stress echocardiography
All patients recruited underwent DSE. The image quality
obtained was interpretable in all patients (1296 [24.3 %]
requiring contrast) and the entire cohort was used in
data analysis. DSE was performed according to a stand-
ard protocol [18] with images acquired in the standard
parasternal long- and short-axis and apical 2-, 3-, and 4-
chamber views. The left ventricle (LV) was divided into
a 17-segment model for qualitative analysis [19] and wall
motion was scored on a 4-point scale (1, normal wall
motion; 2, hypokinesis; 3, akinetic; and 4, dyskinetic) as
is standard [18]. In patients with resting akinetic seg-
ments a biphasic response was used to indicate ischae-
mia. LV ejection fraction was calculated using biplane
Simpson’s technique. LV mass was derived from two-
dimensional motion-mode and indexed to height [20].
Results were classified as a normal response with an
overall increase in wall motion or abnormal response.
An abnormal response was described as the occurrence
under stress of hypokinesia, akinesia or dyskinesia in
one or more resting normal segments and/or worsening
of wall motion in one or more resting hypokinetic seg-
ments [21]. In this way patients were categorised as
non-ischaemic or ischaemic. The extent and location of
inducible ischaemia were evaluated and a wall motion
score index (WMSI) was calculated, both at rest and
during stress. Patients were further categorised with low
(1–3 ischaemic LV segments) or high (>3 ischaemic LV
segments) ischaemic burden. Non-viable myocardium
was defined as severely dysfunctional myocardium with-
out change during DSE [22] and referred to as fixed wall
motion abnormalities (WMA). The territory of myocar-
dial ischaemia was described according to an overlap
model as previously described [23]: Left anterior de-
scending artery (LAD) – anterior wall, anteroseptum,
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mid and apical inferoseptum; Circumflex artery (Cx) –
mid inferolateral wall, basal and mid lateral wall; Right
coronary artery (RCA)/Cx artery – inferior wall, basal
inferolateral wall, basal inferoseptum.
End point definition
The principal end-point of interest for this analysis was
non-fatal cardiac events (NFCE) and secondarily death
from any cause, with patients censored at the time of
the last follow-up. A NFCE was defined as hospitalisa-
tion for myocardial infarction, unstable angina, and time
to coronary revascularisation procedures, defined either
as coronary artery bypass graft surgery or percutaneous
coronary intervention. Hospitalisations were identified
by means of the principle discharge diagnosis. For pa-
tients with multiple events, only the first event was
considered.
Data analysis
Continuous variables are expressed as mean ± SD and cat-
egorical variables as n (%). We used chi-square tests for
discrete variables and one-way analysis of variance tests for
continuous variables to test for differences in demograph-
ics, risk factors and DSE test results between ethnic groups
and between participants with and without end point
events. To describe the frequency of NFCE and all-cause
mortality according to time since DSE, Kaplan-Meier cu-
mulative event curves were constructed and compared
using the log-rank test with a P value <0.05 considered sta-
tistically significant. The data were stratified according to
A) ischaemic and non-ischaemic patients and B) non-
ischaemic (0 segments), low ischaemic burden (1–3 ischae-
mic LV segments) and high ischaemic burden (>3 ischaemic
LV segments) patients for NFCE and all-cause mortality.
Event rates were calculated and expressed as percent per
year. We used Cox proportional-hazards regression to esti-
mate hazard ratios and corresponding 95 % confidence in-
tervals (CI) for NFCE and all-cause mortality for each
individual ethnic group and computed the C statistic (area
under the receiver operator curve) as a measure of the in-
cremental value of DSE beyond that provided by standard
risk factors.
All models were adjusted for age, gender, smoking his-
tory, diabetes, hypercholesterolemia, hypertension, prior
myocardial infarction, prior revascularization and use of
lipid lowering or anti-hypertensive medication. All ana-
lyses were conducted using the statistical package for
social sciences (SPSS 21 release version of SPSS for
Windows; SPSS Inc., Chicago IL, USA).
Results
Study cohort
Of the 6231 patients referred for DSE, 814 did not meet
inclusion criteria and 88 patients were lost at follow-up
and therefore excluded from the final analysis. The
remaining 5329 patients of which 434 (8.1 %) were Afro-
Caribbean, 2219 (41.6 %) were European white and 2676
(50.2 %) were Indian Asian comprised the final study co-
hort (Fig. 1). Afro-Caribbean and Indian Asian patients
had been resident in the UK for 38 ± 15 and 41 ± 17, re-
spectively, and European whites were born in the UK.
The majority of DSE requests were due to suspected an-
gina pectoris (79.7 %) and the remainder were due to
shortness of breath on exertion (20.3 %). The baseline
characteristics of the study cohort varied significantly
among the three ethnic groups, as shown in Table 1.
Briefly, European white patients were significantly older
than both Afro-Caribbean and Indian Asian patients.
The presence of hypertension, diabetes mellitus, hyper-
cholesterolemia and previous percutaneous coronary
intervention was significantly greater in Indian Asians
compared to Afro-Caribbeans and European whites.
Family history of cardiovascular disease and smoking
history was significantly greater in European whites
compared to Afro-Caribbeans and Indian Asians. The
low, intermediate and high pre-test probability of CAD
did not significantly (p = 0.415) differ between ethnic
groups (Table 1).
Baseline atrial fibrillation was present in 82 (1.5 %) pa-
tients, and 116 (2.2 %) had left bundle branch block.
Atrial fibrillation induced by DSE occurred in 27 (0.5 %)
patients, and non-sustained ventricular tachycardia in 2
(0.04 %) patients. None of the patients required intra-
venous beta-blocker to reverse the effects of dobutamine
or treat arrhythmias. Long-term cardiac medication was
similar among all groups and the proportion of patients
prescribed anti-anginal (defined as any treatment alone
or in combination of beta-blockers, calcium antagonists,
or nitrates) medication was similar between groups
(Table 1). The Canadian Cardiovascular Society angina
classification was similar between European white and
Indian Asians, but significantly different from Afro-
Caribbeans.
Importantly, there were significant differences in
baseline cardiac function, structure and geometry be-
tween ethnic groups. Afro-Caribbean patients had a
significantly lower LV end systolic diameter and signifi-
cantly greater LV end diastolic diameter (LVEDD) max-
imal wall thickness, LV mass, and LV mass index
compared to European white and Indian Asian patients
(Table 1). Indian Asian patients had a significantly
smaller LVEDD compared to Afro-Caribbean and
European white patients and a significantly greater LV
ejection fraction compared to European white patients
(Table 1). The cardiovascular risk profile was less
favourable in patients whom went onto have a NFCE
and among those who died during follow-up, as shown
in Table 2.
O’Driscoll et al. Cardiovascular Ultrasound  (2015) 13:36 Page 3 of 12
Clinical outcomes
The mean follow-up time was 4.6 ± 1.3 years (Afro-
Caribbean: 4.6 ± 1.2 years; European white 4.4 ± 1.4
years; Indian Asians 4.8 ± 1.2 years). NFCE occurred in
849 (15.9 %) patients overall and were noted in 12.7 %
(55 events) Afro-Caribbean patients, 16.4 % (363 events)
in European white patients and 16.1 % (431 events) in
Indian Asians. All-cause mortality occurred in 1365
(25.6 %) of patients (24.9 % in Afro-Caribbean patients,
25.4 % in European white patients and 25.9 % in Indian
Asians). There were no significant differences between
ethnic groups regarding NFCE and all-cause mortality.
DSE was completed in all patients and the level of
agreement; kappa between the two sonographers was 0.84.
Consensus was obtained in discordant cases and 90,593
left ventricular segments were analysed. In total 3645
(68.4 %) patients had a normal study, 1174 (22 %) patients
developed a new or worsening WMA (ischaemic re-
sponse) during their DSE, and 859 (16.1 %) had fixed
WMA’s. Of the patients with fixed WMA’s, 349 (40.6 %)
developed a new or worsening WMA during DSE. The
territory of myocardial ischaemia did not significantly
differ between groups (LAD, p = 0.821; Cx, p = 0.748;
RCA, p = 0.975).
During the follow-up period, 958 (18%) patients (85
[19.6 %] Afro-Caribbean, 366 [16.5 %] European white,
507 [18.9 %] Indian Asian) underwent coronary angiog-
raphy within 29 ± 2.2 days of DSE. Of these patients, 561
(58.6 %) had inducible ischaemia during DSE. In total,
530 (9.9 %) patients had significant (defined as ≥70 %
coronary lumen stenosis by visual determination in ≥1
coronary artery) CAD (47 [10.8 %] Afro-Caribbean, 213
Fig 1 Study flow diagram
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Table 1 Baseline demographic characteristics, risk factors and echocardiography measures according to ethnic group
Characteristics Afro-Caribbean (n = 434) European White (n = 2219) Indian Asian (n = 2676) P Value
Demographics
Age (yrs) 63.1 ± 12.6 66.8 ± 12.9 64 ± 11.5 <0.001
Male gender 196 (45.2) 1144 (51.6) 1395 (52.1) 0.079
Height (cm) 169.8 ± 8.7 170.4 ± 8.9 166.6 ± 9.8 <0.001
Weight (kg) 83.4 ± 16.5 81.4 ± 15.8 79 ± 14.5 <0.001
Body mass index (kg · m2) 29 ± 6 28 ± 5.2 28.5 ± 4.9 <0.001
Body surface area (m2) 1.94 ± 0.2 1.93 ± 0.2 1.87 ± 0.2 <0.001
History
Hypertension 247 (56.9) 1228 (55.3) 1624 (60.7) 0.001
Diabetes mellitus 102 (23.5) 451 (20.3) 880 (32.9) <0.001
Hypercholesterolemia 203 (46.8) 967 (43.6) 1441 (53.8) <0.001
Family history of CVD 91 (21) 586 (26.4) 644 (24.1) 0.026
Prior myocardial infarction 30 (6.9) 204 (9.2) 256 (9.6) 0.204
Prior PCI 75 (17.3) 450 (20.3) 732 (27.4) 0.009
Prior CABGS 46 (10.6) 237 (10.7) 359 (13.4) 0.958
Smoking history <0.001
Never smoked 350 (80.6) 1411 (63.6) 2337 (87.3)
Ex-smoker 61 (14.1) 553 (24) 220 (8.2)
Current smoker 23 (5.3) 255 (11.1) 119 (4.4)
Pre-test probability of coronary artery disease 0.415
Low 137 (31.6) 616 (27.8) 723 (27)
Intermediate 164 (37.8) 872 (39.3) 1064 (39.8)
High 133 (30.6) 731 (32.9) 889 (33.2)
NYHA functional class symptom status <0.001
NYHA functional class II 411 (94.7) 1962 (88.4) 2317 (86.6)
NYHA functional class III 23 (5.3) 257 (11.6) 359 (13.4)
Canadian Cardiovascular Society angina classification 0.001
Class I 255 (58.8) 1096 (49.4) 1338 (50)
Class II 153 (35.3) 874 (39.4) 1046 (39.1)
Class III 26 (6) 249 (11.2) 292 (10.9)
Long term cardiac medication
ACE inhibitor 155 (35.7) 817 (36.8) 959 (35.8) 0.759
Angiotensin II receptor antagonist 79 (18.2) 410 (18.5) 545 (20.4) 0.202
Aspirin 244 (56.2) 1211 (54.6) 1529 (57.1) 0.194
Beta blockers 187 (43.1) 962 (43.4) 1136 (42.5) 0.815
Calcium antagonists 140 (32.3) 662 (29.8) 847 (31.7) 0.319
Diuretic 104 (24) 491 (22.1) 605 (22.6) 0.707
Lipid-lowering agents 273 (62.9) 1478 (66.6) 1812 (67.7) 0.139
Nitrates 61 (14.1) 323 (14.6) 403 (15.1) 0.806
Warfarin 20 (4.6) 157 (7.1) 159 (5.9) 0.085
At least 1 anti-anginal medication 285 (65.7) 1404 (63.3) 1721 (64.3) 0.563
Baseline Echocardiography Data
LVESD (cm) 2.9 ± 0.7 3.2 ± 0.6 3.1 ± 0.6 0.009
LVEDD (cm) 4.48 ± 0.6 4.5 ± 0.5 4.38 ± 0.4 <0.001
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[9.6 %] European white, 270 [10.1 %] Indian Asian pa-
tients). The resulting sensitivity, specificity, positive and
negative predictive values for DSE in detecting signifi-
cant CAD were 93.6, 84.8, 88.4 and 91.4 %, respectively.
There were no significant differences between the ethnic
groups in the proportion of patients who underwent cor-
onary angiography (p = 0.181) or the proportion of pa-
tients who had significant coronary disease (p = 0.781).
The NFCE rate for all patients without ischaemia was
2.3 % per year, increasing to 4.8 % for patients with fixed
WMA’s, 7.3 % per year for those with 1–3 ischaemic seg-
ments and highest among those with >3 ischaemic
segments (10.1 % per year). Patients with any ischaemia
during DSE had a cardiac event rate of 7.7 % per year,
suggesting that a positive DSE was associated with 90
extra NFCE per 100 person years of follow-up.
The all-cause mortality event rate for all patients with-
out ischaemia was 4 % per year, increasing to 7.9 % for
those with fixed WMA’s, 10.5 % per year for those with 1–
3 ischaemic segments and highest among those with >3
ischaemic segments (16 % per year). Patients with any is-
chaemia during DSE had a mortality event rate of 11.2 %
per year, suggesting that a positive DSE was associated
with 132 extra deaths per 100 person years of follow-up.
Table 1 Baseline demographic characteristics, risk factors and echocardiography measures according to ethnic group (Continued)
LV ejection fraction (%) 56.6 ± 8.9 56.2 ± 8.9 56.9 ± 7.9 0.023
Maximal LVEDD Wall Thickness (cm) 1.19 ± 0.33 1.11 ± 0.21 1.12 ± 0.24 <0.001
Left atrial size (mm) 38 ± 15 37 ± 11 37 ± 17 0.781
Left ventricular mass (g) 182.8 ± 35.2 169.7 ± 38.6 153.3 ± 34.8 <0.001
Left ventricular mass index (g · m−1) 103.8 ± 21.2 94.1 ± 23.5 89.9 ± 19.4 <0.001
Mitral E/A 1.21 ± 0.4 1.22 ± 0.3 1.22 ± 0.4 0.72
Mitral E Deceleration (ms) 202 ± 55 209 ± 69 203 ± 63 0.623
Mitral E/Ea 9.6 ± 3.9 9.5 ± 4.3 9.6 ± 4.1 0.875
Mitral Annular Calcification 14 (3.2) 73 (3.3) 130 (4.9) 0.014
Mitral Regurgitation 54 (12.4) 315 (14.2) 384 (14.3) 0.564
Aortic Stenosis 15 (3.5) 71 (3.2) 48 (1.8) 0.003
Aortic Regurgitation 14 (3.2) 66 (3) 62 (2.3) 0.274
Dobutamine stress echocardiography test
Baseline heart rate (b · min−1) 69.6 ± 16.1 69.3 ± 18.8 71.1 ± 15.1 0.001
Peak heart rate (b · min−1) 137.1 ± 21.7 131.8 ± 22.7 136.3 ± 19.1 <0.001
Target heart rate achieved 358 (82.5) 1842 (83) 2231 (83.4) 0.943
Baseline sBP (mmHg) 133.3 ± 24.1 131.2 ± 24.8 132.9 ± 24.5 0.039
Peak sBP (mmHg) 160.3 ± 83 147.8 ± 31.5 151.1 ± 31.9 <0.001
Baseline dBP (mmHg) 71.7 ± 18.3 71.3 ± 22.9 70.7 ± 19.6 0.498
Peak dBP (mmHg) 75.1 ± 18.7 72.5 ± 17.6 74.5 ± 18.1 <0.001
Resting wall motion score index 1.03 ± 0.1 1.05 ± 0.13 1.04 ± 0.11 0.006
Peak wall motion score index 1.06 ± 0.13 1.09 ± 0.16 1.08 ± 0.15 0.001
Fixed wall motion abnormality 55 (12.7) 377 (17) 427 (16) 0.078
New wall motion abnormality 69 (15.9) 485 (21.9) 620 (23.2) 0.003
Number of ischaemic LV segments <0.001
0 LV segments 365 (84.1) 1734 (78.1) 2056 (76.8)
1-3 LV segments 61 (14.1) 398 (17.9) 555 (20.7)
>3 LV segments 8 (1.8) 87 (3.9) 65 (2.4)
Outcome
Non-fatal cardiac event 55 (12.7) 363 (16.4) 431 (16.1) 0.149
All-cause mortality 108 (24.9) 564 (25.4) 693 (25.9) 0.870
Note: CVD Cardiovascular disease, PCI Percutaneous coronary intervention, CABGS Coronary artery bypass graft surgery, NYHA New York Heart Association, ACE
Angiotensin converting enzyme, LVESD Left ventricular end systolic dimension, LVEDD Left ventricular end diastolic dimension, LV Left ventricle, sBP systolic blood
pressure, dBP diastolic blood pressure
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Table 2 Baseline demographic characteristics and risk factors according to non-fatal cardiac events and all-cause mortality in all
patients
Parameter No non-fatal cardiac
event (n = 4480)
Non-fatal cardiac
event (n = 849)
P Value Survived
(n = 3964)
All-cause mortality
(n = 1365)
P Value
Demographics
Age (yrs) 64.4 ± 12.4 68.9 ± 11 <0.001 65.1 ± 11.8 65.1 ± 13.5 0.948
Male gender 2315 (51.7) 420 (49.5) 0.451 2124 (53.6) 611 (44.8) <0.001
Ethnic group 0.149 0.870
Black 379 (8.5) 55 (6.5) 326 (8.2) 108 (7.9)
European White 1856 (41.4) 363 (42.8) 1655 (41.8) 564 (41.3)
Indian Asian 2245 (50.1) 431 (50.8) 1983 (50) 693 (50.8)
Weight (kg) 79.3 ± 15.3 80.6 ± 15.2 0.027 78.9 ± 15.2 80.9 ± 15.3 <0.001
Body mass index (kg · m2) 28.3 ± 5.1 28.3 ± 5.1 0.659 28 ± 5 28.4 ± 5.3 0.014
Body surface area (m2) 1.88 ± 0.2 1.9 ± 0.2 0.003 1.88 ± 0.2 1.91 ± 0.2 <0.001
Systolic blood pressure
(mmHg)
132 ± 33 132 ± 39 0.934 131 ± 25 132 ± 25 0.356
Diastolic blood pressure
(mmHg)
70 ± 18 76 ± 30 <0.001 70 ± 20 71 ± 21 0.381
LV ejection fraction (%) 56.9 ± 8.3 55.1 ± 9.2 <0.001 57.2 ± 7.8 54.9 ± 9.9 <0.001
History
Hypertension 2547 (56.9) 552 (65) <0.001 2310 (58.3) 789 (57.8) 0.913
Diabetes mellitus 1154 (25.8) 279 (32.9) <0.001 1043 (26.3) 390 (28.6) 0.104
Hypercholesterolemia 2098 (46.8) 513 (60.4) <0.001 1886 (47.6) 725 (53.1) <0.001
Family history of CVD 1072 (23.9) 249 (29.3) 0.001 926 (23.4) 395 (28.9) <0.001
Prior myocardial infarction 394 (8.8) 96 (11.3) 0.020 356 (9) 134 (9.8) 0.346
Prior PCI 1034 (23.1) 223 (26.3) 0.124 940 (23.7) 317 (23.2) 0.784
Prior CABG 508 (11.3) 134 (15.8) <0.001 431 (10.9) 211 (15.5) <0.001
Smoking history 0.024 0.503
Non-smoker 3474 (77.5) 629 (74.1) 3047 (76.9) 1056 (77.4)
Ex-smoker 690 (15.4) 139 (16.4) 628 (15.8) 201 (14.7)
Current smoker 316 (7.1) 81 (9.5) 289 (7.3) 108 (7.9)
NYHA functional class symptom status <0.001 <0.001
NYHA functional class II 4063 (90.7) 627 (73.9) 3665 (92.5) 1025 (75.1)
NYHA functional class III 417 (9.3) 222 (26.1) 299 (7.5) 340 (24.9)
CCS angina classification <0.001 <0.001
Class I 2689 (60) 0 (0) 2202 (55.5) 487 (35.7)
Class II 1402 (31.3) 671 (79) 1524 (38.4) 549 (40.2)
Class III 389 (8.7) 178 (21) 238 (6) 329 (24.1)
Long term cardiac medication
ACE inhibitor 1632 (36.4) 299 (35.2) 0.551 1443 (36.4) 488 (35.8) 0.648
Angiotensin II receptor
antagonist
861 (19.2) 173 (20.4) 0.404 753 (19) 281 (20.6) 0.206
Aspirin 2578 (57.5) 406 (47.8) <0.001 2176 (54.9) 808 (59.2) 0.006
Beta blockers 1965 (43.9) 320 (37.7) 0.001 1674 (42.2) 611 (44.8) 0.109
Calcium antagonists 1389 (31) 260 (30.6) 0.880 1222 (30.8) 427 (31.3) 0.771
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Dobutamine stress echocardiography as a predictor of
outcome
Figure 2 and Fig. 3 show the unadjusted Kaplan-Meier cu-
mulative event curves for NFCE and all-cause mortality,
respectively, dichotomized according to myocardial ischae-
mia (a) and number of ischaemic LV segments (b). The dif-
ferences amongst these curves were significant (P < 0.001)
and illustrates that myocardial ischaemia and greater is-
chaemic burden translate into significantly worse outcome.
Table 3 and Additional file 1: Table S1 show the risk of
NFCE and all-cause mortality respectively in each of the
three ethnic groups, adjusted for standard risk factors
including age, gender, hypertension, diabetes mellitus,
hypercholesterolemia, family history of CVD, smoking
history, prior myocardial infarction, prior revasculariza-
tion and use of lipid lowering or anti-hypertensive medi-
cation. Among the three ethnic groups, ischaemia on
DSE was associated with 2 to 2.5 times the risk of NFCE
and 1.2 to 1.4 times the risk for all-cause mortality. For
each ethnic group, the risk associated with a NFCE and
all-cause mortality increased as the burden of myocar-
dial ischaemia increased. Importantly, peak WMSI was
Fig 2 Kaplan-Meier hazard curves for the cumulative survival and freedom from non-fatal cardiac events in each ethnic group. Kaplan-Meier
hazard curves dichotomized according to myocardial ischaemia (a) and number of ischaemic LV segments (b)
Table 2 Baseline demographic characteristics and risk factors according to non-fatal cardiac events and all-cause mortality in all
patients (Continued)
Diuretic 1005 (22.4) 195 (23) 0.714 857 (21.6) 343 (25.1) 0.007
Lipid-lowering agents 3027 (67.6) 536 (63.1) 0.017 2614 (65.9) 949 (69.5) 0.017
Nitrates 689 (15.4) 98 (11.5) 0.004 581 (14.7) 206 (15.1) 0.724
Warfarin 271 (6) 65 (7.7) 0.073 245 (6.2) 91 (6.7) 0.530
Note: CVD Cardiovascular disease, PCI Percutaneous coronary intervention, CABGS Coronary artery bypass graft surgery, NYHA New York Heart Association, ACE
Angiotensin converting enzyme
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the strongest independent predictor in all-ethnic groups
for both NFCE and all-cause mortality. All adjusted haz-
ard ratios for DSE parameters are significant (P < 0.038),
for NFCE and all-cause mortality.
Table 4 shows the C-statistic for the prediction of
NFCE and all-cause mortality according to ethnic group,
calculated on the basis of the standard risk factors alone
and on the basis of the standard risk factors in addition
to DSE parameters. The C-statistic for the prediction of
NFCE and all-cause mortality was greater when DSE
parameters were added to standard risk factors. These
increases were statistically significant for each ethnic
group indicating an improvement in discrimination.
Discussion
We examined the predictive value of DSE in a multiethnic
UK population. We found that DSE is a strong and inde-
pendent predictor of NFCE and all-cause mortality irre-
spective of ethnicity. The risk of NFCE and all-cause
mortality was associated with the burden of myocardial is-
chaemia, as assessed by the peak WMSI and the number
of ischaemic segments during DSE. The addition of DSE to
standard risk factor models including age, gender, hyper-
tension, diabetes mellitus, hypercholesterolemia, family
history of CVD, smoking history, prior myocardial infarc-
tion, prior revascularization and use of lipid lowering or
anti-hypertensive medication for the prediction of NFCE
and all-cause mortality significantly increased the C statis-
tic, an order of magnitude comparable to that observed
with coronary calcium scoring in different ethnic popula-
tions [24, 25]. Importantly, DSE parameters contributed to
the risk of both NFCE and all-cause mortality in three
major ethnic groups independently of other risk factors.
The prognostic value of DSE has been previously re-
ported in large studies in patients with various pre-test
probabilities [9, 13, 16, 26–31]. Ischaemic burden and se-
vere wall motion abnormalities during stress were inde-
pendently associated with events in the present study,
findings which previous research have recognised that in-
dicate worse prognosis [9, 13]. However, previous analysis
has not attempted to evaluate the predictive value of DSE
in different ethnic groups. Importantly, in all three ethnic
Fig 3 Kaplan-Meier hazard curves for the cumulative survival and freedom from all-cause mortality in each ethnic group. Kaplan-Meier hazard
curves dichotomized according to myocardial ischaemia (a) and number of ischaemic LV segments (b)
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groups studied, the addition of DSE parameters to clinical
data improved the predictive power. This finding contrasts
prior research, which demonstrated ethnic differences in
the survival of patients undergoing exercise treadmill
testing [8].
This study also demonstrated ethnicity related differ-
ences in the function, structure and geometry of the left
ventricle at rest. Afro-Caribbean patients demonstrated
greater concentric cardiac remodelling with significantly
greater maximal LV wall thickness and LV mass compared
to European white and Indian Asian patients. A greater
LV wall thickness has been shown previously in Afro-
Caribbean populations compared to other ethnic groups
and is associated with an increased mortality risk [32].
Table 3 Risk of non-fatal cardiac events associated with dobutamine stress test result in three ethnic groups
Afro-Caribbean European White Indian Asian
Parameter HR (95 % CI) P HR (95 % CI) P HR (95 % CI) P
Age (yrs) 1.025 (1.000-1.051) 0.050 1.020 (1.009-1.031) 0.001 1.018 (1.008-1.027) 0.002
Male gender 1.366 (0.793-2.353) 0.262 0.967 (0.534-1.752) 0.913 0.870 (0.720-1.052) 0.152
Hypertension 2.201 (1.089-4.449) 0.028 0.910 (0.721-1.149) 0.428 1.040 (0.823-1.315) 0.714
Diabetes mellitus 1.038 (0.549-1.963) 0.909 1.118 (0.865-1.445) 0.393 2.652 (2.538-2.790) <0.001
Hypercholesterolemia 0.831 (0.434-1.590) 0.575 1.773 (1.624-1.959) 0.019 1.347 (1.073-1.691) 0.010
Family history of CVD 1.177 (0.582-2.380) 0.650 1.350 (1.078-1.691) 0.009 0.906 (0.717-1.145) 0.407
Prior myocardial infarction 1.311 (0.552-3.644) 0.164 1.126 (0.792-1.601) 0.509 1.028 (0.743-1.422) 0.868
Prior PCI 0.520 (0.223-1.211) 0.130 0.826 (0.631-1.081) 0.164 0.981 (0.793-1.214) 0.863
Prior CABG 2.496 (1.199-5.198) 0.015 1.043 (0.764-1.424) 0.790 0.781 (0.590-1.034) 0.085
Smoking history 0.565 0.252 0.658
Non-smoker 1 (reference) 1 (reference) 1 (reference)
Ex-smoker 0.738 (0.263-2.076) 0.871 (0.671-1.130) 1.028 (0.709-1.491)
Current smoker 1.260 (0.365-4.347) 1.375 (1.004-1.885) 1.326 (0.867-2.027)
ACE inhibitor 0.963 (0.507-1.830) 0.909 0.989 (0.780-1.253) 0.925 1.029 (0.833-1.272) 0.788
Angiotensin II receptor antagonist 1.090 (0.513-2.313) 0.823 1.099 (0.822-1.469) 0.524 1.158 (0.909-1.474) 0.236
Beta blockers 0.965 (0.532-1.751) 0.906 0.805 (0.644-1.008) 0.059 0.766 (0.625-0.939) 0.010
Calcium antagonists 1.532 (0.838-2.801) 0.166 0.871 (0.685-1.108) 0.261 0.985 (0.801-1.212) 0.888
Lipid-lowering agents 0.969 (0.509-1.843) 0.922 0.715 (0.579-0.883) 0.002 0.868 (0.701-1.073) 0.191
Fixed wall motion abnormality 0.879 (0.116-1.240) 0.109 0.933 (0.628-1.384) 0.729 0.827 (0.555-1.234) 0.353
Resting wall motion score index 0.749 (0.220-9.947) 0.304 1.489 (1.200-1.848) 0.008 1.991 (1.985-1.997) 0.003
Peak wall motion score index 2.273 (2.114-17.483) 0.038 3.092 (3.026-6.306) <0.001 3.643 (3.254-12.033) <0.001
New wall motion abnormality 2.026 (1.121-2.351) <0.001 2.105 (1.166-2.251) <0.001 2.490 (1.340-4.620) <0.001
Number of Ischaemic LV Segments <0.001 <0.001 <0.001
0 LV segments 1 (reference) 1 (reference) 1 (reference)
1-3 LV segments 1.092 (1.036-1.238) 1.171 (1.121-1.242) 1.62 (1.44-4.18)
>3 LV segments 2.192 (2.146-4.238) 2.803 (2.567-5.138) 3.040 (2.68-7.70)
Note: CVD Cardiovascular disease, PCI Percutaneous coronary intervention, CABGS Coronary artery bypass graft surgery, ACE Angiotensin converting enzyme
Table 4 C-statistic for risk factors alone and for risk factors plus dobutamine stress test results to predict non-fatal cardiac events
and all-cause mortality
Ethnic Group Non-fatal cardiac event All-cause mortality
C-statistic for risk
factors alone
C-statistic for risk factors plus
DSE test results
P value C-statistic for risk
factors alone
C-statistic for risk factors plus
DSE test results
P value
Afro-Caribbean 0.67 0.74 0.009 0.6 0.72 0.004
European White 0.68 0.76 <0.001 0.61 0.72 <0.001
Indian Asian 0.64 0.74 <0.001 0.57 0.69 <0.001
Total 0.64 0.74 <0.001 0.61 0.68 <0.001
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Furthermore, an increased LV mass has been shown to be
a powerful independent predictor for CVD morbidity and
mortality in individuals previously free of clinical cardio-
vascular disease [33]. Treatment to control modifiable risk
factors in Afro-Caribbean populations may reduce cardiac
remodelling [34]. Indian Asian patients had a significantly
smaller LV cavity and the smallest LV mass compared to
Afro-Caribbean and European white patients. Other stud-
ies support these findings [34–36]. Indexing LV mass did
not attenuate the observed difference. A decreased LV cav-
ity and smaller LV mass may lead to an increase in LV wall
stress and myocardial oxygen demand, which may in-
crease the vulnerability to myocardial ischaemia [34]. This
was a specific cohort of patients referred for DSE. These
differences may contribute to the elevated CVD risk seen
in Afro-Caribbean and Indian Asian ethnic groups. It is
important to note that European white patients were sig-
nificantly older than both Afro-Caribbean and Indian
Asian patients. Therefore, for an age matched cohort the
prevalence of CVD may be significantly different between
ethnic groups.
Angiographic comparisons of CAD between Caucasians
and Asians have reported similar findings to the present
study. Dhawan and Bray [37] reported no difference in the
severity or extent of CAD between Caucasians and Asians.
As shown in our study, there was a significant difference
in age between groups, with Asians being significantly
younger than Caucasians. In a recent study including
279,256 patients, South Asians were younger, had more
extensive coronary artery disease and greater prevalence
of major risk factors, particularly diabetes compared to
Caucasians [38]. However, as shown in our study, when
correcting for these differences, outcome was similar be-
tween South Asians and Caucasians. Similar to our study,
angiographic differences in CAD were minimal among
African American compared to white patients, with a
similar distribution of coronary vessel disease and mean
stenosis score [39].
Disproportionate rates of heart disease are seen in racial
and ethnic minority populations. The ability to reliably
risk stratify populations at greater risk of adverse cardiac
events is therefore of great importance. Recently, cardio-
vascular screening demonstrated the potential to reduce
ethnic health inequalities [40]. In our study Indian Asians
had a significantly greater prevalence of hypertension, dia-
betes mellitus, and hypercholesterolemia compared to
Afro-Caribbeans and European whites. However, a signifi-
cantly greater proportion of Indian Asians had previous
coronary intervention compared to Afro-Caribbeans and
European whites. In addition, Indian Asian and European
whites had greater Canadian Cardiovascular Society an-
gina classification compared to Afro-Caribbeans. Irre-
spective of differences in risk factors, the results of this
study indicate that DSE adds incremental value in
estimating the probability of cardiac events and all-cause
mortality in three major ethnic groups and is therefore a
valuable tool in the assessment of CAD.
Our study has limitations. This was a prospective obser-
vational study from a single centre. Patients recruited into
our study were referred for a clinically indicated DSE and
there is the potential for referral bias and high pre-test
probability related to a higher prevalence of co-morbidities
and symptoms. Only 18.9 % on the study populations
underwent coronary angiography within 1-month of DSE,
which may bias test sensitivity and specificity. Medication
listed refers to treatment at time of DSE and changes in
medication over the follow-up period were not taken into
account. Due to difficulties in accurately determining the
cause of death by reviewing death certificates or medical re-
cords, all-cause mortality was selected as a more objective
and unbiased end point [41]. Notwithstanding these limita-
tions, the present study is consistent with earlier work and
extends our knowledge in different ethnic populations.
Conclusions
In a multiethnic UK cohort, DSE added incremental value
to the prediction of NFCE and all-cause mortality over
that of standard CVD risk factors in Afro-Caribbean,
European white and Indian Asian patients.
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